PATENT

ATTORNEY DOCKET NO. 06727/006001

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert A. Murgita

Art Unit:

Serial No.: 08/377,316

Examiner:

: January 24, 1995

Filed

: RECOMBINANT HUMAN ALPHA-FETOPROTEIN AS A CELL Title

PROLIFERATIVE AGENT

Commissioner of Patents and Trademarks

Washington, DC 20231

Application Branch Attention:

RESPONSE TO NOTICE TO FILE MISSING PARTS OF APPLICATION

Responsive to the Notice to File Missing Parts of Application under 37 CFR 1.53(d) mailed March 13, 1995 (a copy of which is enclosed), Applicant as a small entity submits herewith the following:

> A Combined Declaration and Power of Attorney in compliance with 37 CFR 1.63.

Payment of the surcharge of \$65.00 for late filing of the declaration.

Verified statements of small entity status

It is understood that this perfects the application and no additional papers or filing fees are required. If there are any other charges, or any credits, please apply them to Deposit Account No. 06-1050.

> Date of Deposit I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Jano

Respectfully submitted,

Date: 6/26/95

KAREN F. LECH KAREN PEG NO — 35, 238

Paul T. Clark Reg. No. 30,162

Fish & Richardson P.C. 225 Franklin Street Boston, MA 02110-2804

Telephone: 617/542-5070 Facsimile: 617/542-8906

121389.B11

Application No. 08/3773/6

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.	
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).	
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.82	:1(e)
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."	
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).	ре
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing as required by 37 CFR 1.821(e).	g"
7. Other:	_
Applicant must provide:	
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"	
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification	
A statement that the content of the paper and computer readable copies are the same and, where applicable, include new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)	no
For questions regarding compliance with these requirements, please contact:	
For Rules Interpretation, call (703) 308-1123	

For CRF submission help, call (703) 308-4212 For Patentin software help, call (703) 308-6856

PATENT

ATTORNEY DOCKET NO. 06727/006001

Art Unit: Examiner:

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert A. Murgita
Serial No.: 08/377,316

Filed : January 24, 1995

Title

: RECOMBINANT HUMAN ALPHA-FETOPROTEIN AS A CELL

PROLIFERATIVE AGENT

Commissioner of Patents and Trademarks Washington, DC 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

In response to the communication dated March 13, 1995, applicant submits herewith a Sequence Listing in computer readable form as required by 37 CFR §1.824. In addition, applicant submits a Sequence Listing as required under 37 CFR §1.823(a) and a statement under 37 CFR §1.821(b).

I hereby state that this submission, filed in accordance with 37 CFR §1.821(g), does not contain new matter.

Respectfully submitted,

Date: 6/26/95

KAREN F. LECH

Paul T. Clark Reg. No. 30,162 35,238

Fish & Richardson P.C. 225 Franklin Street Boston, MA 02110-2804

Telephone: 617/542-5070 Facsimile: 617/542-8906

121389.B11

Date of Deposit

| Date of Deposit | June 37 (FIR 18(a) that this correspondence of the second of th

I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Trademarks, Washington, D.C. 20231.

nary Tane DiPalma

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

/	·
	1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e)
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
(5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
	5. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
	7. Other:
Appli	cant must provide:
	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
•	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no ew matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For CRF submission help, call (703) 308-4212

For Rules Interpretation, call (703) 308-1123

For Patentin software help, call (703) 308-6856